High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and
development have led to a growing interest in repurposing “old” drugs to treat both common …

Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset
of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their …

The cellular barriers are major bottlenecks for bioactive compounds entering into cells to
accomplish their biological functions, which limits their biomedical applications …

During the past recent years, various therapies emerged in the era of breast cancer. Breast
cancer is a heterogeneous disease in which genetic and environmental factors are involved …

Cell therapy practices date back to the 19th century and continue to expand on
investigational and investment grounds. Cell therapy includes stem cell-and non–stem cell …

Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …

Abstract Background Cancer stem cells (CSCs) are considered as the major cause to tumor
initiation, recurrence, metastasis, and drug resistance, driving poor clinical outcomes in …

Radiotherapy (RT) is a modality of oncologic treatment that can be used to treat
approximately 50% of all cancer patients either alone or in combination with other treatment …

Since the introduction of the cancer stem cell (CSC) paradigm, significant advances have
been made in understanding the functional and biological plasticity of these elusive …

CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of
patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy …